kilerb, with this kind of volume, should be a good play for a couple days. This is OTC land, anything can happened, be quick to react that's the only advice I can tell you.
posted
Have you noticed how many times the Bid and Ask were the same? And a few times where the bid was higher than the ask? What does that usually mean? That they need shares?
-------------------- "As long as there are dreamers, there are dreams that will come true." Posts: 862 | From: CT Yankee..... in FLA | Registered: Aug 2005
| IP: Logged |
posted
A little profit taking there at the end. Does it settle down on Monday or go a little higher? Any thoughts?
Posts: 344 | From: Berkeley, CA | Registered: Sep 2005
| IP: Logged |
posted
Yeah, I still got it. Hopefully, it will go back up. Seems like a cutting edge company selling at a bargain price.
Posts: 344 | From: Berkeley, CA | Registered: Sep 2005
| IP: Logged |
posted
DNAPrint Pharmaceuticals to Combine Computer Modeling With Genetics to Improve Drug Development 11/8/2005
SARASOTA, FL, Nov 08, 2005 (MARKET WIRE via COMTEX) -- DNAPrint(TM) genomics, Inc. (OTC BB: DNAG) today announced that DNAPrint Pharmaceuticals, Inc.'s Computational Biology Division, which was recently acquired from Kenna Technologies, Inc., is preparing to launch its services contract business for the pharmaceutical and biotechnology industries.
By incorporating DNAPrint's pharmacogenomics contract services with those of the Computational Biology Division, the end result will be a unique solution for optimizing clinical trials. DNAPrint will demonstrate to drug developers that they can learn more about a new drug's patient benefit as well as an optimum dosing regimen.
The computational biology scientists at DNAPrint Pharmaceuticals have developed a system for analyzing complex biological processes. "Our offering is pragmatic," says Dr. Barbara Handelin, General Manager of Computational Biology. "Even with an imperfect understanding of disease and human physiology, we have shown that we can create highly predictive models that improve the understanding of researchers. We are especially excited to demonstrate to potential clients how modeling can work synergistically with genetic studies of drug response."
DNAPrint genomics utilizes a proprietary technology that measures variations among patient populations that relate to their responses to drugs. The combination of the two technologies will assist developers of pharmaceutical products in identifying important patient factors that impact how a specific drug will affect different groups of patients. Some of these factors are inborn, such as genetic markers; others are identified by the Company's computer simulations, which will be inherent to the role of the drug in the disease under treatment. The Company will also help identify genetic and other patient factors predisposing patients to toxic side effects.
DNAPrint also uses simulations to model the molecular and cellular effects of a drug candidate so that researchers can ask many more "what if" questions about dose levels and scheduling as opposed to actual human or animal studies. These simulations then guide the design of actual clinical trials with advanced "intelligence" about the likely outcomes. The likelihood of successful trials, targeted to the right patients with an effective dosing regimen is greatly enhanced; and could lead to reduced time and costs of clinical studies.
"We invite everyone to use our services," said Hector J. Gomez, M.D., Ph.D., DNAPrint's Chairman and Chief Medical Officer. "We believe that bringing computer modeling and genetics together is a natural fit for optimizing drug discovery and development. These are independent approaches that together start to improve preclinical and clinical development from strictly empirical medicinal chemistry trials to mechanistically driven human biology studies."
"Simply put, DNAPrint will utilize computational modeling to develop drugs more efficiently," said DNAPrint President and Chief Executive Officer Richard Gabriel. "It will play a valuable role in any company's efforts to pursue the development of drugs which maximize efficacy and minimize side effects by tailoring medications for specific individuals and well-defined population sectors."
Posts: 1364 | From: Somebody from Europe | Registered: Sep 2005
| IP: Logged |
posted
DNAPrint Genomics and SeraCare's Genomics Collaborative Combine to Improve Outcome for Ovarian Cancer Treatment
Monday , November 14, 2005 07:00 ET
SARASOTA, FL AND OCEANSIDE, CA, Nov 14, 2005 (MARKET WIRE via COMTEX) -- DNAPrint(TM) genomics, Inc. (OTC BB: DNAG) and the Cambridge, Mass.-based Genomics Collaborative Division of SeraCare Life Sciences, Inc., today announced that they have begun collaboration on a project designed to improve treatment for patients with ovarian cancer.
"The goal is to identify genetic factors that will enable physicians to predict the outcome and efficacy of carboplatin/tamoxifen treatment, a standard therapy for victims of breast cancer," stated Hector J. Gomez, M.D., Ph.D., Chairman and Chief Medical Officer of DNAPrint genomics. "Combining Genomics Collaborative's extensive network of physician-managed centers with DNAPrint's proprietary genetic testing, the genetic characteristics of 200 women will be studied by comparing those who responded to a standard carboplatin/tamoxifen regimen for breast cancer with those who did not."
"We anticipate that the study's findings may enable physicians to identify likely non-responders before initiation of carboplatin/tamoxifen therapy so that an alternative treatment can be utilized from the outset," stated Kevin Krenitsky, M.D., Senior Vice President and Division Head of Genomics Collaborative. "We hope to improve the outcome of treatment for patients afflicted with this challenging condition."
This marks the second collaborative project between DNAPrint and Genetics Collaborative.
About SeraCare Life Sciences
SeraCare Life Sciences, Inc. is a manufacturer and supplier of biological materials and services essential for the use and manufacture of diagnostic tests and the discovery, development and commercial production of pharmaceuticals. The Company's offerings include plasma-based therapeutic products, diagnostic products and reagents, cell culture products, specialty plasmas, in vitro stabilizers, and the Global Repository(R), comprised of clinical samples (DNA, RNA, tissue, and serum) for use in the drug discovery and development processes. SeraCare is headquartered in Oceanside, CA, and maintains facilities in Cambridge and West Bridgewater, MA; Frederick and Gaithersburg, MD; and Hatboro, PA. For more information please visit http://www.seracare.com.
About DNAPrint
DNAPrint genomics, Inc. (www.dnaprint.com) is a developer of genomics-based products and services in two primary markets: biomedical and forensics. DNAPrint Pharmaceuticals, Inc., a wholly owned subsidiary, develops diagnostic tests and theranostic products (drug/test combinations) using the Company's proprietary ancestry-informed genetic marker studies combined with proprietary computational modeling technology. Computational Biology and Pharmacogenomics services are also offered externally to biopharmaceutical companies. The Company's first theranostic product is PT-401, a "Super EPO" (erythropoietin) dimer protein drug for treatment of anemia in renal dialysis patients (end stage renal disease). Pre-clinical and clinical development of all the company's drug candidates will benefit from simulated pre-trials to better design actual trials and are targeted to patients with a genetic profile indicating their propensity to have the best clinical response. DNAPrint is proud of its continued dedication to developing and supplying new technological advances in law enforcement and consumer ancestry heritage interests. Please refer to www.dnaprint.com for information on law enforcement and consumer applications which include DNAWITNESS(TM), RETINOME(TM), ANCESTRYbyDNA(TM) and EURO-DNA(TM).
Forward Looking Statements
All statements in this press release that are not historical are forward-looking statements. Such statements are subject to risks and uncertainties that could cause actual results to differ materially from those projected, including, but not limited to, uncertainties relating to technologies, product development, manufacturing, market acceptance, cost and pricing of DNAPrint's products, dependence on collaborations and partners, regulatory approvals, competition, intellectual property of others, and patent protection and litigation. DNAPrint genomics, Inc. expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in DNAPrint's expectations with regard thereto or any change in events, conditions, or circumstances on which any such statements are based.
Company Contact: Richard Gabriel President and CEO 941-366-3400 -or- Ron Stabiner The Wall Street Group, Inc. 212-888-4848
SOURCE: DNAPrint Genomics, Inc.
Copyright 2005 Market Wire, All rights reserved
Posts: 2691 | Registered: Dec 2003
| IP: Logged |
DNAPrint genomics to Acquire Ellipsis Biotherapeutics
Tuesday , November 15, 2005 07:00 ET
SARASOTA, FL, Nov 15, 2005 (MARKET WIRE via COMTEX) -- DNAPrint(TM) genomics, Inc. (OTC BB: DNAG), a developer of genomics-based products and services, today announced that it has entered into an agreement to acquire the clinical genomics and genotyping assets of Ellipsis Biotherapeutics Corporation ("Ellipsis"), a privately held drug and diagnostic discovery company based in Toronto, Canada.
Under terms of the agreement, Ellipsis is selling these core assets for 6,500,000 shares of DNAPrint genomics common stock. Pending completion of DNAPrint due diligence and Ellipsis shareholder approval, the transaction is expected to be completed by Nov. 30, 2005. DNAPrint will retain Ellipsis' employees, management and business operations. In addition, DNAPrint will retain the Ellipsis Biotherapeutics name and operate Ellipsis Biotherapeutics as a subsidiary of DNAPrint genomics.
"Ellipsis has developed novel drug technologies and has spun those operations out," stated Hector J. Gomez, M.D., Ph.D., DNAPrint Chairman and Chief Medical Officer and head of its wholly owned DNAPrint Pharmaceuticals, Inc. subsidiary. "The value for DNAPrint is that Ellipsis' platform technology is highly compatible with our mission to expand our capabilities and increase our revenues."
Richard Gabriel, DNAPrint President and Chief Executive Officer, noted that DNAPrint is actively involved in development of pharmacogenomics through in-house research, licensing agreements and the acquisition of synergistic technologies, all targeting future growth for the Company. "Our recent acquisition of Kenna Technologies, which builds computer models that mimic complex biological systems, as well as Ellipsis' synergistic gene platform applications, will broaden our capabilities and add to the growing number of products in our pipeline."
Ellipsis is located in downtown Toronto adjacent to the academic health science complex and major teaching hospitals. Using the Beckman Coulter GenomeLab SNPstream and the Illumina Beadstation, Ellipsis performs contract SNP genotyping for academic centers, hospitals, human health care corporations and biotech companies. Its diverse services include human, plant and animal analyses.
"We are very excited to become part of the DNAPrint group of companies," stated Dr. Laurence Rubin, Chief Executive Officer of Ellipsis. "Our core competencies provide a unique fit for the future growth and development of our contract services as well as opportunity to participate in novel research programs and collaborations."
About DNAPrint
DNAPrint genomics, Inc. (www.dnaprint.com) is a developer of genomics-based products and services in two primary markets: biomedical and forensics. DNAPrint Pharmaceuticals, Inc., a wholly owned subsidiary, develops diagnostic tests and theranostic products (drug/test combinations) using the Company's proprietary ancestry-informed genetic marker studies combined with proprietary computational modeling technology. Computational Biology and Pharmacogenomics services are also offered externally to biopharmaceutical companies. The Company's first theranostic product is PT-401, a "Super EPO" (erythropoietin) dimer protein drug for treatment of anemia in renal dialysis patients (end stage renal disease). Pre-clinical and clinical development of all the Company's drug candidates will benefit from simulated pre-trials to better design actual trials and are targeted to patients with a genetic profile indicating their propensity to have the best clinical response. DNAPrint is proud of its continued dedication to developing and supplying new technological advances in law enforcement and consumer ancestry heritage interests. Please refer to www.dnaprint.com for information on law enforcement and consumer applications which include DNAWITNESS(TM), RETINOME(TM), ANCESTRYbyDNA(TM) and EURO-DNA(TM).
Forward Looking Statements
All statements in this press release that are not historical are forward-looking statements. Such statements are subject to risks and uncertainties that could cause actual results to differ materially from those projected, including, but not limited to, uncertainties relating to technologies, product development, manufacturing, market acceptance, cost and pricing of DNAPrint's products, dependence on collaborations and partners, regulatory approvals, competition, intellectual property of others, and patent protection and litigation. DNAPrint genomics, Inc. expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in DNAPrint's expectations with regard thereto or any change in events, conditions, or circumstances on which any such statements are based.
Company Contact: Richard Gabriel President and CEO 941-366-3400 -or- Ron Stabiner The Wall Street Group, Inc. 212-888-4848
SOURCE: DNAPrint genomics, Inc.
Copyright 2005 Market Wire, All rights reserved.
Posts: 2691 | Registered: Dec 2003
| IP: Logged |
UBBFriend: Email this page to someone!
Printer-friendly view of this topic
